替奈普酶生物类似药(Generium Pharmaceuticals)(Tenecteplase biosimilar(Generium Pharmaceuticals)) - 药物靶点：PLG_在研适应症：ST段抬高心肌梗死_专利_临床

概要

基本信息

药物类型

生物类似药、酶

别名

靶点

PLG

作用机制

PLG刺激剂(纤溶酶原刺激剂)

治疗领域

心血管疾病

在研适应症

ST段抬高心肌梗死

非在研适应症-

原研机构

Generium ZAO

在研机构

Generium ZAO

非在研机构-

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

序列信息

Sequence Code 431641667

当前序列信息引自: *****

关联

2

项与替奈普酶生物类似药(Generium Pharmaceuticals) 相关的临床试验

NCT05601999 / Recruiting临床3期

Multicenter Randomized Single Blind Study of the Clinical Efficacy and Safety of GNR-060 (JSC "GENERIUM", Russia) Compared to Metalyse (Boehringer Ingelheim Pharma GmbH & Co.KG, Germany) in Patients With ST Elevation Myocardial Infarction

GNR-060(JSC "GENERIUM", Russia) is a proposed biosimilar to the referent product Metalyse. This study is to compare the clinical efficacy and safety of GNR-060 vs Metalyse as a thrombolitic agent in patients with with ST Elevation Myocardial Infarction (STEMI).

开始日期2021-09-03

申办/合作机构

Generium ZAO

NCT00222651 / Terminated临床2期

A Phase II Multicenter, Randomized, Double Blind Study Comparing the Efficacy and Safety of Single Bolus i.v. Tenecteplase Versus Placebo in Normotensive Patients With Pulmonary Embolism and Right Ventricular Dysfunction

To assess the efficacy and safety of Tenecteplase versus Placebo in normotensive patients with sub-massive Pulmonary Embolism and Right Ventricular Dysfunction (RVD) all receiving unfractionated heparin (UFH)

开始日期2004-07-01

申办/合作机构